US, Japanese immunologists awarded Tang Prize for cancer quest

June 19, 2014

An American and a Japanese immunologist were Thursday named joint recipients of the Tang Prize, touted as Asia's version of the Nobels, for their contributions in the fight against cancer.

James P. Allison of the MD Anderson Cancer Center at the University of Texas, and Tasuku Honjo of Kyoto University beat out some 100 nominees from around the world to take the inaugural in the category of biopharmaceutical sciences.

"This is an exciting time in our fight against ," the Tang Prize Foundation said.

"Their pioneering research has led to a new field in the therapy of cancers, which are already the leading killers to mankind," Chen Chien-jen, vice president of Taiwan's top academic body Academia Sinica, told reporters.

Allison, currently chair of Immunology and director of Immunotherapy Platform at the University of Texas, was one of the two scientists to identify the ligand CTLA-4 as an inhibitory receptor on T-cells in 1995, and was the first to recognise it as a potential target for .

T-cells are a type of lymphocyte that play a central role in cell-mediated immunity.

Research by Allison's team has led to the development of a monoclonal antibody drug, which was approved by the US Food and Drug Administration (FDA) in 2011 for the treatment of melanoma.

Honjo discovered the ligand PD-1, also an inhibitory receptor on T-cells, in 1992. Antibodies against PD-1 have been approved by the FDA as an investigational new drug and developed for the treatment of cancer.

Yun Yen, president of Taipei Medical University, said that outlook for the related drugs are promising as combination therapy, a mixture of anti-CTLA-4 and anti-PD-1, has been shown to enhance the long-term survival rates in cancer patients.

Named after China's Tang Dynasty (AD 618-907), the Asian prize was founded by Taiwanese billionaire Samuel Yin in 2012 with a donation of Tw$3 billion.

Former Norwegian premier Gro Harlem Brundtland was named Wednesday as the first recipient of the prize for her work as the "godmother" of sustainable development.

Winners in the last two categories—Sinology (the study of China) and "rule of law"—will be unveiled Friday and Saturday.

The winner in each category will receive Tw$50 million ($1.7 million), with Tw$40 million in cash and the remainder in a research grant—a richer purse than the eight million Swedish kronor ($1.2 million) that comes with a Nobel Prize.

Explore further: Taiwan billionaire launches Asian 'Nobel prize' (Update)

Related Stories

Taiwan billionaire launches Asian 'Nobel prize' (Update)

January 28, 2013
One of Taiwan's richest men on Monday launched what has been widely touted as the Asian equivalent of the Nobel Prize, and it is even more lucrative than the famed Swedish award.

Long-term results encouraging for combination immunotherapy for advanced melanoma

June 2, 2014
The first long-term follow-up results from a phase 1b immunotherapy trial combining drugs for advanced melanoma patients has shown encouraging results—long-lasting with high survival rates—researchers report. First author ...

T cell repertoire changes predictive of anti-CTLA-4 cancer immunotherapy outcome revealed

May 28, 2014
Sequenta, Inc. today announced publication of a study done in collaboration with researchers from UCSF and UCLA that used the company's proprietary LymphoSIGHT immune repertoire sequencing platform to investigate the effects ...

Investigational drug may increase survival for some patients with advanced melanoma

March 4, 2014
An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial ...

Biomarker identifies melanoma patients who may respond to immunotherapy MK-3475

April 7, 2014
Among melanoma patients treated with the PD-1 inhibitor MK-3475, those whose tumors had the protein PD-L1 had better immune responses and higher survival rates, according to results presented here at the AACR Annual Meeting ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.